DE69810635D1 - Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust - Google Patents

Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust

Info

Publication number
DE69810635D1
DE69810635D1 DE69810635T DE69810635T DE69810635D1 DE 69810635 D1 DE69810635 D1 DE 69810635D1 DE 69810635 T DE69810635 T DE 69810635T DE 69810635 T DE69810635 T DE 69810635T DE 69810635 D1 DE69810635 D1 DE 69810635D1
Authority
DE
Germany
Prior art keywords
preventing
hearing loss
treating hearing
neurturin protein
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69810635T
Other languages
English (en)
Other versions
DE69810635T2 (de
Inventor
Ella Magal
M Delaney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE69810635D1 publication Critical patent/DE69810635D1/de
Application granted granted Critical
Publication of DE69810635T2 publication Critical patent/DE69810635T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dairy Products (AREA)
DE69810635T 1997-07-30 1998-07-17 Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust Expired - Fee Related DE69810635T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5418497P 1997-07-30 1997-07-30
US09/106,486 US6043221A (en) 1997-07-30 1998-06-29 Method for preventing and treating hearing loss using a neuturin protein product
PCT/US1998/014600 WO1999006064A1 (en) 1997-07-30 1998-07-17 Method for preventing and treating hearing loss using a neurturin protein product

Publications (2)

Publication Number Publication Date
DE69810635D1 true DE69810635D1 (de) 2003-02-13
DE69810635T2 DE69810635T2 (de) 2003-05-28

Family

ID=26732740

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69810635T Expired - Fee Related DE69810635T2 (de) 1997-07-30 1998-07-17 Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust

Country Status (10)

Country Link
US (2) US6043221A (de)
EP (1) EP1005358B1 (de)
JP (1) JP2001525316A (de)
AT (1) ATE230607T1 (de)
AU (1) AU8658298A (de)
CA (1) CA2298414C (de)
DE (1) DE69810635T2 (de)
DK (1) DK1005358T3 (de)
ES (1) ES2190093T3 (de)
WO (1) WO1999006064A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
WO2000073764A2 (en) 1999-06-01 2000-12-07 Baylor College Of Medicine Composition and methods for the therapeutic use of an atonal-associated sequence
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
DE10025152A1 (de) * 2000-05-23 2001-12-06 Marlies Knipper Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
AU2003208900A1 (en) * 2002-01-30 2003-09-02 House Ear Institute L-carnitine for treatment of hearing loss
EP1507553A2 (de) 2002-05-29 2005-02-23 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Pankreas spezifische proteine
DE60335723D1 (de) * 2002-06-27 2011-02-24 Nippon Medical School Foundation Verfahren zum nachweis von perilymphatischen fisteln
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
DE60332748D1 (de) * 2002-10-02 2010-07-08 Anges Mg Inc Arzneimittel gegen hörfunktionsstörungen
CA2549994A1 (en) 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
WO2005051415A1 (en) 2003-11-27 2005-06-09 Develogen Aktiengesellschaft Method for preventing and treating diabetes using neurturin
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
WO2005123140A2 (en) * 2004-06-08 2005-12-29 Alza Corporation Preparation of macromolecular conjugates by four-component condensation reaction
EP1765459B1 (de) 2004-06-15 2018-11-28 Cochlear Limited Automatischer nachweis der schwelle einer evozierten nervenreaktion
CN101137359B (zh) * 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US9265933B2 (en) 2005-09-08 2016-02-23 Massachusetts Eye And Ear Infirmary Cochlear implants containing biological cells and uses thereof
EP1872790A1 (de) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft Neue Zusammensetzung zur Erhöhung der Bioverfügbarkeit von Neurturin
CA2742839A1 (en) * 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2278999A4 (de) 2008-04-21 2015-04-22 Otonomy Inc Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
EP2493918A4 (de) * 2009-10-30 2013-04-10 Ntf Therapeutics Inc Verbesserte neurturinmoleküle
US20110195872A1 (en) * 2010-02-10 2011-08-11 Richard Selinfreund Devices and systems for biomarker detection
US20150359804A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
FR3024361B1 (fr) * 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
WO2020045980A1 (en) * 2018-08-28 2020-03-05 Industry-Academic Cooperation Foundation, Yonsei University Pharmaceutical composition for treating or preventing sensorineural hearing loss
CN110124014A (zh) * 2019-05-16 2019-08-16 杭州师范大学 重组人神经突起生长因子Neuritin蛋白的应用及一种用于治疗听神经病的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
DE69430824T2 (de) * 1993-08-12 2003-01-23 Neurotech Sa Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
AU1121997A (en) * 1995-11-29 1997-06-19 Amgen, Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product

Also Published As

Publication number Publication date
US6043221A (en) 2000-03-28
JP2001525316A (ja) 2001-12-11
ATE230607T1 (de) 2003-01-15
CA2298414C (en) 2004-09-28
DK1005358T3 (da) 2003-02-24
CA2298414A1 (en) 1999-02-11
ES2190093T3 (es) 2003-07-16
AU8658298A (en) 1999-02-22
WO1999006064A1 (en) 1999-02-11
DE69810635T2 (de) 2003-05-28
EP1005358A1 (de) 2000-06-07
EP1005358B1 (de) 2003-01-08
US6274554B1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
DE69810635T2 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
ATE211392T1 (de) Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69527052D1 (de) Verwendung von Wasser mit verringertem Deuterium-Gehalt zur Herstellung von hygienischen und kosmetischen Präparaten
ATE319712T1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69833297D1 (de) Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS)
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE60040860D1 (de) Mechanisch verlängerte neuronale zellen und methoden zur herstellung und verwendung dieser zellen
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
EP1304119A3 (de) Verfahren zur Vorbeugung und Behandlung von Gehörverlust mit Neurturin Protein
NZ323207A (en) Hemoregulatory compounds
AU4210900A (en) Products and methods for treating ptp lar related diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee